Dallas Conference • April 8-9, 2016

The objective of the conference series is to deliver a comprehensive educational update highlighting the most clinically relevant advances in chronic liver and gastrointestinal (GI) diseases. The 1.5-day conferences cover topics ranging from upper GI disorders, viral hepatitis, cirrhosis, inflammatory bowel disease and irritable bowel syndrome.

Goal Statement

To deliver a comprehensive educational update highlighting the most clinically relevant advances in chronic liver and gastrointestinal (GI) diseases. The 1.5-day conferences focus on topics such as upper GI disorders, viral hepatitis, fatty liver disease, primary biliary cholangitis, cirrhosis, inflammatory bowel disease, and irritable bowel syndrome.

Target Audience

Gastroenterologists, hepatologists, internists, family practitioners, surgeons, physician assistants, nurse practitioners, fellows/residents in training, registered nurses, and other healthcare professionals with an interest in GI and liver disease.

Statement of Need/Program Overview

Digestive diseases include a wide spectrum of disorders affecting the oropharynx and alimentary canal, liver and biliary system, and pancreas. Chronic GI disorders are common in the US, and the prevalence is increasing.

Considerable overlap can be found in the symptoms of serious GI diseases and the symptoms of benign or functional GI diseases. Noninvasive diagnostic tests, sensible clinical evaluation plans, and a clear understanding of disease progression will enhance patient assessment/management and identify the right patients for referral to GI specialists. For patients with a confirmed diagnosis of a chronic GI disorder, advances in the understanding of the clinical impact of evolving treatment options offer new choices for managing these conditions.

The conference format will consist of lectures, Q&A/panel discussions, and parallel breakout sessions for in-depth discussions of high interest topics.

CME Learning Objectives

Upon completion of this conference, participants should be better able to:
  • Describe evolving patient management and treatment strategies for chronic liver and GI diseases
  • Integrate significant advances in therapeutic and diagnostic modalities into clinical practice
  • Discuss the latest clinical research, including future therapies and their role in the context of the current clinical paradigm

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Gastrointestinal and Liver Association of the Americas (GALA), and the Texas Liver Institute. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Nursing Accreditation Statement

Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 11.0 contact hours may be earned for successful completion of this activity.

Disclosure of Conflicts of Interest

All faculty and staff involved in the planning or presentation of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. John Bayliss, VP, Business Development, spouse is an employee of Amgen Inc.; no other staff at the Annenberg Center for Health Sciences at Eisenhower or the Gastrointestinal and Liver Association of the Americas (GALA) have relationships to disclose.

Learner Assurance Statement

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower. The information is presented for the purpose of advancing the attendees' professional development.

Americans with Disabilities Act

The event staff will be glad to assist you with any special needs (ie, physical, dietary). Please contact us prior to the event at 1-877-925-9535.

This activity is supported by educational grants from AbbVie Inc.; Alexion Pharmaceuticals, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Merck & Co., Inc.; Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC.; and Takeda Pharmaceuticals U.S.A., Inc.

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower, the Gastrointestinal and Liver Association of the Americas (GALA), and the Texas Liver Institute.